Neovascularization Induced by Mechanical Barrier disrUption and Systemic Erythropoietin in Patients With Cerebral Perfusion Deficits (NIMBUS Trial)

Trial Profile

Neovascularization Induced by Mechanical Barrier disrUption and Systemic Erythropoietin in Patients With Cerebral Perfusion Deficits (NIMBUS Trial)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2017

At a glance

  • Drugs Erythropoietin (Primary)
  • Indications Anaemia
  • Focus Pharmacodynamics
  • Acronyms NIMBUS
  • Sponsors Dong-A ST
  • Most Recent Events

    • 04 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top